Background: Pulmonary metastases occur in 10-20% of patients with colorectal cancer and significantly influence long-term survival. In this study, the immunological architecture of colorectal lung in comparison to liver metastases and its impact on patient survival were examined. Methods: Specimens of patients with colorectal lung and liver metastases were stained for HE, CD4, CD8, CD20, CD68 and CD45RO. Besides histomorphological evaluation, immunohistochemical stainings were analyzed for the respective cell numbers separately for tumor area, infiltrative margin and distant lung or liver stroma. These findings were correlated with clinical data and patient outcome. Results: In colorectal lung (n = 69) in comparison to liver (n = 222) metastases, the immunological focus is located in the tumor region. A high CD4+ cell infiltration of this area is associated with prolonged survival of patients after resection of colorectal lung metastases [103 ± 33 (high) vs. 37 ± 6 months (low); p = 0.0246]. Patients who were treated with preoperative chemotherapy did not show differences in immune infiltrates compared to chemotherapy-naïve patients. Conclusion: Colorectal lung and liver metastases showed a distinct immunological architecture. A dense cell infiltration of colorectal lung metastases by CD4+ cells was related to prolonged patient survival. Preoperative chemotherapy did not influence cellular immune infiltrates.

Keywords:
Prognostic parameters, Cellular infiltration, Immune infiltrate, Tumor microenvironment
1.
Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
2.
Bindea G, Mlecnik B, Fridman WH, Galon J: The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011;33:335-340.
3.
Brunner SM, Kesselring R, Rubner C, Martin M, Jeiter T, Boerner T, et al: Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg 2014;101:1681-1691.
4.
Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, et al: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009;69:2685-2693.
5.
Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, et al: Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2011;344:1-24.
6.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
7.
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666.
8.
Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-1102.
9.
Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-1271.
10.
Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al: The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
11.
Dave RV, Pathak S, White AD, Hidalgo E, Prasad KR, Lodge JP, et al: Outcome after liver resection in patients presenting with simultaneous hepatopulmonary colorectal metastases. Br J Surg 2015;102:261-268.
12.
Qiu M, Hu J, Yang D, Cosgrove DP, Xu R: Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 2015;6:38658-38666.
13.
Treasure T, Milosevic M, Fiorentino F, Macbeth F: Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax 2014;69:946-949.
14.
Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, et al: Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
15.
Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-5951.
16.
Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, et al: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013;19:4079-4091.
17.
Stoll G, Bindea G, Mlecnik B, Galon J, Zitvogel L, Kroemer G: Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015;6:11894-11909.
18.
Vacchelli E, Semeraro M, Enot DP, Chaba K, Poirier Colame V, Dartigues P, et al: Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget 2015;6:20840-20850.
19.
Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P: Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013;20:572-579.
20.
Brandi G, Derenzini E, Falcone A, Masi G, Loupakis F, Pietrabissa A, et al: Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. Clin Colorectal Cancer 2013;12:188-194.
21.
Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-4911.
22.
Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al: Long-term results of lung metastasectomy: prognostic analyses based on 5,206 cases. J Thorac Cardiovasc Surg 1997;113:37-49.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.